Skip to content

Research at St Andrews

NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis

Research output: Contribution to journalArticlepeer-review

DOI

Open Access permissions

Open

Author(s)

M. Richardson, J. Kirkham, K. Dwan, D. J. Sloan, G. Davies, A. L. Jorgensen

School/Research organisations

Abstract

BACKGROUND: Tuberculosis (TB) patients receiving anti-tuberculosis treatment may experience serious adverse drug reactions (ADRs) such as hepatotoxicity. Variants of the N-acetyltransferase 2 (NAT2) gene may increase the risk of experiencing such toxicity events.
OBJECTIVE : To provide a comprehensive evaluation of the evidence base for associations between NAT2 variants and anti-tuberculosis drug-related toxicity. METHOD: This was a systematic review and metaanalysis. We searched for studies in Medline, PubMed, EMBASE, BIOSIS and Web of Science.We included data from 41 articles (39 distinct cohorts of patients). We pooled effect estimates for each genotype on each outcome using meta-analyses stratified by country. RESULTS: We assessed the quality of the included studies, which was variable, with many areas of concern. Slow/intermediate NAT2 acetylators were statistically significantly more likely to experience hepatotoxicity than rapid acetylators (OR 1.59, 95%CI 1.26-2.01). Heterogeneity was not detected in the overall pooled analysis (I2 = 0%). NAT2 acetylator status was significantly associated with the likelihood of experiencing anti-tuberculosis drugrelated hepatotoxicity.
CONCLUSION: We encountered several challenges in performing robust syntheses of data from pharmacogenetic studies, and we outline recommendations for the future reporting of pharmacogenetic studies to enable high-quality systematic reviews and meta-analyses to be performed.
Close

Details

Original languageEnglish
Pages (from-to)293-305
Number of pages13
JournalInternational Journal of Tuberculosis and Lung Disease
Volume23
Issue number3
DOIs
Publication statusPublished - 1 Mar 2019

    Research areas

  • Tuberculosis, Pharmacogenetics, Adverse events, Evidence synthesis

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Molecular detection of mycobacterium tuberculosis in oral mucosa from patients with presumptive tuberculosis

    Molina-Moya, B., Ciobanu, N., Hernandez, M., Prat-Aymerich, C., Crudu, V., Adams, E. R., Codreanu, A., Sloan, D. J., Cuevas, L. E. & Dominguez, J., 21 Dec 2020, In: Journal of Clinical Medicine. 9, 12, 7 p., 4124.

    Research output: Contribution to journalArticlepeer-review

  2. All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era

    Stagg, H. R., Flook, M., Martinecz, A., Kielmann, K., Abel Zur Wiesch, P., Karat, A. S., Lipman, M. C. I., Sloan, D. J., Walker, E. F. & Fielding, K. L., 2 Nov 2020, In: ERJ Open Research. 6, 4, 13 p., 00315-2020.

    Research output: Contribution to journalReview articlepeer-review

  3. STrengthening the Reporting Of Pharmacogenetic Studies: development of the STROPS guideline

    Chaplin, M., Kirkham, J. J., Dwan, K., Sloan, D. J., Davies, G. & Jorgensen, A. L., 21 Sep 2020, In: PLoS Medicine. 17, 9, 11 p., e1003344.

    Research output: Contribution to journalArticlepeer-review

  4. Utility of broad-spectrum antibiotics for diagnosing pulmonary tuberculosis in adults: a systematic review and meta-analysis

    Divala, T. H., Fielding, K. L., Kandulu, C., Nliwasa, M., Sloan, D. J., Gupta-Wright, A. & Corbett, E. L., 1 Sep 2020, In: Lancet Infectious Diseases. 20, 9, p. 1089-1098 10 p.

    Research output: Contribution to journalArticlepeer-review

Related by journal

  1. International Journal of Tuberculosis and Lung Disease (Journal)

    Stephen Henry Gillespie (Editor)

    2011

    Activity: Publication peer-review and editorial work typesEditor of research journal

Related by journal

  1. Equitable tuberculosis care in the North West of England: analysis of tuberculosis cohort review data

    MacPherson, P., Squire, S. B., Cleary, P., Davies, S., Wake, C., Dee, K., Walker, J., Farrow, S., McMaster, P., Woodhead, M., Sloan, D. J. & North West TB Audit Steering Committee, 1 Jun 2016, In: International Journal of Tuberculosis and Lung Disease. 20, 6, p. 778-785 8 p.

    Research output: Contribution to journalArticlepeer-review

  2. Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings

    Sabiiti, W., Mtafya, B., Kuchaka, D., Azam, K., Viegas, S., Mdolo, A., Farmer, E., Khonga, M., Evangelopoulos, D., Honeyborne, I., Rachow, A., Heinrich, N., Ntinginya, N. E., Bhatt, N., Davies, G. R., Jani, I. V., McHugh, T. D., Kibiki, G., Hoelscher, M., Gillespie, S. H. & 1 others, PANBIOME (Pan-African Biomarker Expansion Programme) consortium, 1 Aug 2016, In: International Journal of Tuberculosis and Lung Disease. 20, 8, p. 1004-1009

    Research output: Contribution to journalArticlepeer-review

  3. Tuberculosis in the time of Ebola: Obstacles and opportunities

    Sloan, D. J. & O'Dempsey, T. J., 1 Nov 2015, In: International Journal of Tuberculosis and Lung Disease. 19, 11, p. 1269 1 p.

    Research output: Contribution to journalEditorialpeer-review

ID: 262877095

Top